Table 4—

Incremental and construct validity: NeuroQoL and SF-12 measures as predictors of overall quality of life

PredictorsBaseline modelModel 1 (SF-12 only)Model 2 (NeuroQoL only)Model 3 (SF-12 and NeuroQoL)
NDS−0.15*−0.05−0.020.02
Painful symptoms(−0.37)NA−0.22−0.16*
Symptoms of reduced feeling(−0.33)NA−0.12−0.11
Sensory motor symptoms(−0.38)NA−0.21*−0.14
SF-12 PCS(0.41)0.41NA0.25
r20.1210.2570.2870.322
Ulcer−0.13−0.08−0.10−0.08
Painful symptoms(−0.41)NA−0.25−0.19*
Symptoms of reduced feeling(−0.33)NA−0.09−0.07
Sensory motor symptoms(−0.39)NA−0.20−0.14
SF-12 PCS(0.42)0.42NA−0.23
r20.1120.2600.2950.327
NDS−0.15*−0.11−0.00−0.04
Activity limitations(−0.38)NA−0.09−0.12
Interpersonal-emotional burden(−0.53)NA−0.47−0.22*
SF-12 MCS(0.52)0.52NA0.36
r20.1180.3740.3500.429
Ulcer−0.13−0.120.02−0.03
Activity limitations(−0.39)NA−0.10−0.12
Interpersonal-emotional burden(−0.53)NA−0.46−0.22*
SF-12 MCS(0.52)0.52NA0.36
r20.1100.3720.3500.427
  • Note: cell entries are standardized regression (β) coefficients, controlling for country, age, sex, education, marital status, type of diabetes, duration of diabetes, sequelae of diabetes, and concomitant diseases. Baseline model shows β coefficient for NDS or ulcer and in parentheses the β-to-enter (β if only that one scale were added to the baseline model) for NeuroQoL and SF-12 measures; r2 for the baseline model does not include any NeuroQoL or SF-12 measures. Models 1–3 show coefficients for NDS/ulcer and all NeuroQoL and SF-12 measures in that model; variables not included are designated.

  • *

    * P < 0.01;

  • P < 0.001;

  • P < 0.05. NA, not applicable.